Clozapine utilization and outcomes by race in a public mental health system: 1994-2000
Clozapine utilization and outcomes by race in a public mental health system: 1994-2000
复制标题
DOI：
10.4088/jcp.v67n0911
复制
发表时间：
2006-09-01
影响因子：
5.3
通讯作者：
Conley, Robert R.
中科院分区：
文献类型：
--
作者：
Kelly, Deanna L.;Dixon, Lisa B.;Conley, Robert R.
目的：本研究的目的是评估种族差异，氯氮平处方，剂量，症状表现和反应，和住院状态。本研究扩展了以前的研究，氯氮平通过检查患者和治疗相关的因素，可能有助于解释或消除的原因差异prescribing.Method：氯氮平记录为373白色和非洲裔美国人精神分裂症或精神情感障碍治疗1994年3月1日至2000年12月31日，在住院精神卫生设施的状态马里兰州进行了检查。本研究的记录来自3个马里兰州数据库：氯氮平授权和监测计划，马里兰州抗精神病药物数据库和健康维护信息系统数据库。总共有10.3%的非洲裔美国人精神分裂症患者中有150例（150/1458）接受过氯氮平治疗，而白人患者中有15.3%（223/1453）接受过氯氮平治疗（χ 2 = 16.74，DF = 1，P
Objective: This study aimed to assess racial differences in clozapine prescribing, dosing, symptom presentation and response, and hospitalization status. This study extends previous studies of clozapine by examining patient- and treatment-related factors that may help explain or eliminate reasons for differential prescribing.Method: Clozapine records for 373 white and African American patients with schizophrenia or schizoaffective disorder treated between March 1, 1994, and December 31, 2000, in inpatient mental health facilities in the state of Maryland were examined. Records for this study were derived from 3 state of Maryland databases: the Clozapine Authorization and Monitoring Program, the State of Maryland Antipsychotic Database, and the Health Maintenance Information System Database.Results: A total of 10.3% of African Americans (150/1458) with schizophrenia received clozapine treatment compared with 15.3% of whites (223/1453) (chi(2) = 16.74, df = 1, p